ES2160637T3 - Derivados de k-252a que mejoran la actividad inducida por la neurotrofina. - Google Patents

Derivados de k-252a que mejoran la actividad inducida por la neurotrofina.

Info

Publication number
ES2160637T3
ES2160637T3 ES94929228T ES94929228T ES2160637T3 ES 2160637 T3 ES2160637 T3 ES 2160637T3 ES 94929228 T ES94929228 T ES 94929228T ES 94929228 T ES94929228 T ES 94929228T ES 2160637 T3 ES2160637 T3 ES 2160637T3
Authority
ES
Spain
Prior art keywords
neurotrophin
activity induced
derivatives
improve
particularly preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929228T
Other languages
English (en)
Inventor
Marcie A Glicksman
David P Rotella
Nicola Neff
Chikara Murakata
Robert L Hudkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2160637T3 publication Critical patent/ES2160637T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTAN DERIVADOS DE K-252A DE ALCALOIDES DE INDOLOCARBAZOLA DE LA FORMULA (I-IV), UTILES PARA MEJORAR LA ACTIVIDAD INDUCIDA POR LA NEUROTROFINA DE LAS CELULAS SENSIBLES A LA NEUROTROFINA. UNA NEUROTROFINA PARTICULARMENTE PREFERIDA ES NT-3, Y UNA CELULA SENSIBLE A LA NEUROTROFINA PARTICULARMENTE PREFERIDA ES UNA QUE COMPRENDA EL RECEPTOR TRK. LA ACTIVIDAD MEJORADA INDUCIDA POR NEUROTROFINA OCASIONADA POR LOS DERIVADOS DE K-252A PRESENTADOS PUEDE DETERMINARSE MEDIANTE LAS SIGUIENTES PRUEBAS: ACTIVIDAD CHAT; SUPERVIVENCIA NEURONAL DE DRG; O DIVISION CELULAR (MITOGENESIS).
ES94929228T 1993-09-16 1994-09-16 Derivados de k-252a que mejoran la actividad inducida por la neurotrofina. Expired - Lifetime ES2160637T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/122,893 US5468872A (en) 1993-09-16 1993-09-16 K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
ES2160637T3 true ES2160637T3 (es) 2001-11-16

Family

ID=22405467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929228T Expired - Lifetime ES2160637T3 (es) 1993-09-16 1994-09-16 Derivados de k-252a que mejoran la actividad inducida por la neurotrofina.

Country Status (14)

Country Link
US (2) US5468872A (es)
EP (1) EP0719268B1 (es)
JP (2) JP3943126B2 (es)
KR (1) KR100186912B1 (es)
AT (1) ATE203751T1 (es)
AU (1) AU693480B2 (es)
CA (1) CA2171561C (es)
DE (1) DE69427862T2 (es)
ES (1) ES2160637T3 (es)
FI (1) FI961236A0 (es)
HU (1) HU222570B1 (es)
NO (1) NO309228B1 (es)
NZ (2) NZ274355A (es)
WO (1) WO1995007911A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3064992A (en) * 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
CA2144940A1 (en) * 1994-03-18 1995-09-19 Chikara Murakata Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
WO1997005141A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Staurosporine analogues
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
CN1285836A (zh) * 1997-12-31 2001-02-28 赛福伦公司 3′－差向异构的K－252a衍生物
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
HK1040053B (en) 1998-09-25 2007-09-21 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
EP1101113A4 (en) * 1999-06-09 2002-05-08 Ljl Biosystems Inc CELL SIGNALING TESTS
US6472385B1 (en) * 1999-08-09 2002-10-29 Trustees Of Darmouth College Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
FR2798931B1 (fr) * 1999-09-22 2001-11-16 Oreal Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6555677B2 (en) * 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
IL157909A0 (en) 2001-03-22 2004-03-28 Bristol Myers Squibb Co Indolopyrrolocarbazole derivatives and pharmaceutical compositions containing the same
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
MY171292A (en) * 2008-12-22 2019-10-07 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds
CN103242404A (zh) * 2012-02-03 2013-08-14 复旦大学 N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
CN103012417B (zh) * 2013-01-08 2015-01-07 中国科学院昆明植物研究所 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60257652A (ja) * 1984-06-02 1985-12-19 Canon Inc 画像処理装置
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5231001A (en) * 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0593663A4 (en) * 1991-07-03 1996-10-30 Regeneron Pharma Method and assay system for neurotrophin activity
AU3064992A (en) * 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
JPH05247056A (ja) * 1992-03-03 1993-09-24 Kyowa Hakko Kogyo Co Ltd インドロカルバゾール誘導体
DE4217963A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Verwendung von Indolocarbazolen zur Behandlung von AIDS
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
NO961087L (no) 1996-05-13
HU9600657D0 (en) 1996-05-28
WO1995007911A1 (en) 1995-03-23
US5468872A (en) 1995-11-21
KR960704894A (ko) 1996-10-09
JPH09502730A (ja) 1997-03-18
AU7836394A (en) 1995-04-03
JP2005220141A (ja) 2005-08-18
DE69427862T2 (de) 2002-04-11
JP3943126B2 (ja) 2007-07-11
EP0719268A1 (en) 1996-07-03
FI961236L (fi) 1996-03-15
NZ314037A (en) 2000-09-29
CA2171561C (en) 1999-08-03
US5516772A (en) 1996-05-14
NZ274355A (en) 1997-03-24
AU693480B2 (en) 1998-07-02
HUT74679A (en) 1997-01-28
NO309228B1 (no) 2001-01-02
FI961236A7 (fi) 1996-03-15
KR100186912B1 (ko) 1999-05-01
EP0719268B1 (en) 2001-08-01
DE69427862D1 (de) 2001-09-06
CA2171561A1 (en) 1995-03-23
NO961087D0 (no) 1996-03-15
ATE203751T1 (de) 2001-08-15
HU222570B1 (hu) 2003-08-28
FI961236A0 (fi) 1996-03-15

Similar Documents

Publication Publication Date Title
CA2171561A1 (en) K-252a Derivatives Which Enhance Neurotrophin-Induced Activity
ES2103061T3 (es) Derivados de n-isoxazol-naftilsulfonamida y su uso como antagonistas de la endotelina.
ES2134226T3 (es) Derivados de s-triazina como fotoestabilizadores.
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
ES2101331T3 (es) Derivados de k-252a.
DE3750612D1 (de) Cc-1065 analoge.
DK115791A (da) Heparinfragmenter som inhibitorer af proliferering af glatte muskelceller
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
ES2017611T3 (es) Tiazoles sustituidos y su uso como fungicidas.
NZ334095A (en) 6-heterocyclic (such as pyran or tetrahydrofuran) substituted adenosine derivatives
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
ES2189941T3 (es) Derivados de nucleosidos aciclicos.
ES2072784T3 (es) Benzo- y piridopiridonas substituidas con sulfonilbencilo.
KR880007076A (ko) 오플록사신을 함유하는 외용제제
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
PE47196A1 (es) DERIVADO 2,7-SUSTITUIDO DE OCTAHIDRO-1H-PIRIDO[1,2-a]PIRAZINA
ES2048793T3 (es) Antibioticos antifungicos.
DK31391D0 (da) Pentacycliske triterpenoidforbindelser som topoisomeraseinhibitorer eller celledifferentieringsfremkaldere
NO20003397L (no) 3 '-epimerie K-252A-derivater
ES2070961T3 (es) Oxadiazolil-fenoxialquilisoxazoles y su uso como agentes antiviricos.
ES2103167B1 (es) Compuestos disazoicos reactivos con las fibras.
CA2022425A1 (en) 1,3,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
DK423186D0 (da) Spiro-(benzofuran-2(3h),1`cycloheptan)-derivater, deres fremstilling og anvendelse samt mellemprodukt til fremstillingen
ES2004489A4 (es) Gametocidas de piridina.
DK0574857T3 (da) Polycycliske 31668P- og 31668U-forbindelser, fremgangsmåder til deres fremstilling samt deres anvendelse som antibiotiske eller antitumorale lægemidler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 719268

Country of ref document: ES